These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23807604)

  • 21. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.
    Chiloiro S; Mazziotti G; Giampietro A; Bianchi A; Frara S; Mormando M; Pontecorvi A; Giustina A; De Marinis L
    Pituitary; 2018 Jun; 21(3):302-308. PubMed ID: 29397538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acromegaly: a new therapy.
    Friend KE
    Cancer Control; 2002; 9(3):232-5. PubMed ID: 12090246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New medical therapies of acromegaly.
    Maffezzoni F; Frara S; Doga M; Mazziotti G; Giustina A
    Growth Horm IGF Res; 2016; 30-31():58-63. PubMed ID: 27745780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic Predictors of Response to Different Medical Therapies in Acromegaly.
    Ramos-Leví AM; Bernabeu I; Sampedro-Núñez M; Marazuela M
    Prog Mol Biol Transl Sci; 2016; 138():85-114. PubMed ID: 26940388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Growth hormone receptor antagonist in the treatment of acromegaly].
    Hubina E; Tóth A; Kovács GL; Dénes J; Kovács L; Góth M
    Orv Hetil; 2011 May; 152(18):709-14. PubMed ID: 21498159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigational therapies for acromegaly.
    Grasso LF; Pivonello R; Colao A
    Expert Opin Investig Drugs; 2013 Aug; 22(8):955-63. PubMed ID: 23731031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of endocrine disease: GH excess: diagnosis and medical therapy.
    Andersen M
    Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination treatment with somatostatin analogues and pegvisomant in acromegaly.
    Neggers SJ; van der Lely AJ
    Growth Horm IGF Res; 2011 Jun; 21(3):129-33. PubMed ID: 21498099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth-hormone and prolactin excess.
    Colao A; Lombardi G
    Lancet; 1998 Oct; 352(9138):1455-61. PubMed ID: 9808008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment.
    Roemmler J; Steffin B; Gutt B; Schneider HJ; Sievers C; Bidlingmaier M; Schopohl J
    Growth Horm IGF Res; 2010 Oct; 20(5):338-44. PubMed ID: 20598600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pegvisomant Treatment in Acromegaly.
    Neggers SJ; Muhammad A; van der Lely AJ
    Neuroendocrinology; 2016; 103(1):59-65. PubMed ID: 25792221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of acromegaly: future.
    Donangelo I; Melmed S
    Endocrine; 2005 Oct; 28(1):123-8. PubMed ID: 16311419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm.
    Clemmons DR; Chihara K; Freda PU; Ho KK; Klibanski A; Melmed S; Shalet SM; Strasburger CJ; Trainer PJ; Thorner MO
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4759-67. PubMed ID: 14557452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term experience of pegvisomant therapy as a treatment for acromegaly.
    Higham CE; Chung TT; Lawrance J; Drake WM; Trainer PJ
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):86-91. PubMed ID: 19018786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New formulations and approaches in the medical treatment of acromegaly.
    Debono M; Newell-Price J
    Curr Opin Endocrinol Diabetes Obes; 2010 Aug; 17(4):350-5. PubMed ID: 20502324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
    Cozzi R; Attanasio R; Lodrini S; Lasio G
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients.
    Gatta B; Hau DH; Catargi B; Roger P; Tabarin A
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):477-8. PubMed ID: 16181243
    [No Abstract]   [Full Text] [Related]  

  • 39. [Acromegaly: new principles for treatment].
    Jørgensen JO; Feldt-Rasmussen UF; Andersen M; Kristensen LØ; Laurberg P; Weeke J
    Ugeskr Laeger; 2007 Mar; 169(10):904-6. PubMed ID: 17359733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly.
    Mattar P; Alves Martins MR; Abucham J
    Neuroendocrinology; 2010; 92(2):120-7. PubMed ID: 20802256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.